LONDON/COPENHAGEN (Reuters) -Novo Nordisk has appointed U.S. pharmaceutical executive Greg Miley as its new head of corporate affairs, as the obesity drugmaker faces growing pressure from U.S. President Donald Trump on drug pricing.

Miley, an American, is currently senior vice president of government affairs at U.S. pharmaceutical giant AbbVie ( ABBV ). He posted a statement on LinkedIn on Friday and Novo Nordisk shared the statement with Reuters.

Novo's new CEO Mike Doustdar is trying to revive investor confidence through a major restructuring aimed at sharpening Novo's focus in a fierce obesity drug battle against U.S. rival Eli Lilly.

The overhaul includes cutting 9,000 jobs, with 5,000 positions being eliminated in Denmark and layoffs underway across multiple U.S. departments.

AbbVie ( ABBV ) did not immediately reply to a request for comment. Novo Nordisk sent Reuters Miley's statement on LinkedIn when asked for a comment. Miley did not immediately reply when contacted by Reuters earlier on Friday.